NMRA

NMRA

USD

Neumora Therapeutics Inc. Common Stock

$2.878+0.318 (12.422%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$2.560

高値

$2.920

安値

$2.550

出来高

1.60M

企業ファンダメンタルズ

時価総額

480.9M

業種

バイオテクノロジー

United States

取引統計

平均出来高

1.36M

取引所

NMS

通貨

USD

52週レンジ

安値 $0.611現在値 $2.878高値 $14.09

関連ニュース

GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel

もっと見る
Neumora Therapeutics to Participate in Upcoming Conferences in November
Analyst Upgrades

Needham Maintains Buy on Neumora Therapeutics, Raises Price Target to $8

Needham analyst Ami Fadia maintains Neumora Therapeutics with a Buy and raises the price target from $6 to $8.

もっと見る
Needham Maintains Buy on Neumora Therapeutics, Raises Price Target to $8
Analyst Upgrades

Guggenheim Upgrades Neumora Therapeutics to Buy, Announces $14 Price Target

Guggenheim analyst Yatin Suneja upgrades Neumora Therapeutics from Neutral to Buy and announces $14 price target.

もっと見る
Guggenheim Upgrades Neumora Therapeutics to Buy, Announces $14 Price Target
GlobeNewswire

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading

もっと見る
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model